PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31584354-7	2019	DEX markedly elevated the MKP3 expression and modestly reduced the MKP1 expression, with insignificant difference in the latter.	Dexmedetomidine	0-3	dual specificity phosphatase 1	Mus musculus	67-71	
35551994-0	2022	Dexmedetomidine protects against acute lung injury in mice via the DUSP1/MAPK/NF-kappaB axis by inhibiting miR-152-3p.	Dexmedetomidine	0-15	dual specificity phosphatase 1	Mus musculus	67-72	
35551994-12	2022	miR-125-3p overexpression or sh-DUSP1 partially abolished the protection of Dex on MPMVECs.	Dexmedetomidine	76-79	dual specificity phosphatase 1	Mus musculus	32-37	
35551994-14	2022	sh-DUSP1 partially averted the protection of Dex on MPMVECs.	Dexmedetomidine	45-48	dual specificity phosphatase 1	Mus musculus	3-8	
35551994-15	2022	Dex inhibited the activation of the MAPK/NF-kappaB pathway in MPMVECs mediated by LPS, which was partially reversed by sh-DUSP1.	Dexmedetomidine	0-3	dual specificity phosphatase 1	Mus musculus	122-127	
35551994-16	2022	The p38 MAPK inhibitor SB203580 antagonized the protective effect of Dex on MPMVECs mediated by sh-DUSP1.	Dexmedetomidine	69-72	dual specificity phosphatase 1	Mus musculus	99-104	
35551994-18	2022	CONCLUSION: Dex relieved ALI in mice via the DUSP1/MAPK/NF-kappaB axis by down-regulating miR-152-3p.	Dexmedetomidine	12-15	dual specificity phosphatase 1	Mus musculus	45-50